Search

Ginger C Rakestraw

from Somerville, MA
Age ~44
Get Report
Also known as:
Ginger Chao Rakestraw, Ginger Chao
Phone and address:
65 Hall Ave, Somerville, MA 02144
(617) 767-6449
Related to:
Jim Chao, 70Barbara Katherine Mahony, 73Geoffrey Harold, 48Andrew D Harold, 49Suzanne Harold, 53Suzanne Kiefer, 64
Connected to:
Amy L Rakestraw, 50Erich B Rakestraw, 51Jacob K Rakestraw, 37Kendra L Rakestraw, 62Lauren Rakestraw, 31Lonnie J Rakestraw, 60Timothy Rakestraw, 49Tina M Rakestraw, 62Aleksandar Raketic, 54Michael Raketich, 49

Ginger Rakestraw Phones & Addresses

  • 65 Hall Ave, Somerville, MA 02144 (617) 767-6449
  • Cambridge, MA
  • Beaumont, TX
  • Houston, TX

Publications

Us Patents

Fibronectin Based Scaffold Domain Proteins That Bind To Pcsk9

View page
US Patent:
20120094909, Apr 19, 2012
Filed:
Apr 13, 2011
Appl. No.:
13/085864
Inventors:
Ray Camphausen - Wayland MA, US
Jonathan H. Davis - Auburndale MA, US
Sharon T. Cload - Cambridge MA, US
Fabienne M. Denhez - Arlington MA, US
Dasa Lipovsek - Cambridge MA, US
Ching-Hsiung Frederick Lo - Pennington NJ, US
Chee Meng Low - Allston MA, US
Bowman Miao - Churchville PA, US
Tracy S. Mitchell - Billerica MA, US
Rex A. Parker - Titusville NJ, US
Ginger C. Rakestraw - Cambridge MA, US
Katie A. Russo - Watertown MA, US
Doree F. Sitkoff - Dresher PA, US
International Classification:
C07K 19/00
A61K 38/39
US Classification:
514 93, 530395, 5303873, 530363
Abstract:
The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

Antibodies Against Human Trem-1 And Uses Thereof

View page
US Patent:
20220332817, Oct 20, 2022
Filed:
Jul 15, 2020
Appl. No.:
17/627085
Inventors:
- Princeton NJ, US
Joseph TOTH - Belmont MA, US
Ginger C. RAKESTRAW - Somerville MA, US
International Classification:
C07K 16/28
A61P 29/00
A61P 37/00
C12N 15/63
Abstract:
Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Antibodies And Antigen Binding Peptides For Factor Xia Inhibitors And Uses Thereof

View page
US Patent:
20220220220, Jul 14, 2022
Filed:
Jan 7, 2022
Appl. No.:
17/570649
Inventors:
- Princeton NJ, US
- Titusville NJ, US
Ginger Chao Rakestraw - Cambridge MA, US
Christina Terragni - Cambridge MA, US
Andrew Karl Dilger - Princeton NJ, US
Jason Robert Pinckney - Cambridge MA, US
Steven Sheriff - Princeton NJ, US
Kevin Kish - Princeton NJ, US
Yongmi An - Princeton NJ, US
William R. Ewing - Princeton NJ, US
Aaron Paul Yamniuk - Vancouver, CA
International Classification:
C07K 16/36
C07K 16/44
A61P 7/04
G01N 33/86
G01N 33/94
Abstract:
The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.

Anti-Nkg2A Antibodies And Uses Thereof

View page
US Patent:
20220204618, Jun 30, 2022
Filed:
Feb 11, 2022
Appl. No.:
17/670398
Inventors:
- Princeton NJ, US
Alan J. Korman - Piedmont CA, US
Shrikant Deshpande - Fremont CA, US
Amy D. Jhatakia - Fremont CA, US
Richard Y. Huang - Bridgewater NJ, US
Guodong Chen - East Brunswick NJ, US
Ginger C. Rakestraw - Somerville MA, US
Karla Ann Henning - Milpitas CA, US
Vangipuram S. Rangan - Pleasant Hill CA, US
Christine Bee - San Francisco CA, US
Xiang Shao - Los Altos CA, US
International Classification:
C07K 16/28
A61K 39/395
A61P 35/00
Abstract:
The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Anti-Nkg2A Antibodies And Uses Thereof

View page
US Patent:
20220195042, Jun 23, 2022
Filed:
Feb 10, 2022
Appl. No.:
17/668807
Inventors:
- Princeton NJ, US
Alan J. Korman - Piedmont CA, US
Shrikan Deshpande - Fremont CA, US
Amy D. Jhatakia - Fremon CA, US
Richard Y. Huang - Bridgewater NJ, US
Guodong Chen - East Brunswick NJ, US
Ginger G. Rakestraw - Somerville MA, US
Karla Ann Henning - Milpitas CA, US
Vangipuram S. Rangan - Pleasant Hill CA, US
Christine Bee - San Francisco CA, US
Xiang Shao - Los Altos CA, US
International Classification:
C07K 16/28
C07K 1/22
C12N 5/071
C12N 15/85
C12P 21/00
Abstract:
The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Anti-Mertk Antibodies For Treating Cancer

View page
US Patent:
20210395392, Dec 23, 2021
Filed:
Oct 8, 2019
Appl. No.:
17/284119
Inventors:
- Princeton NJ, US
Michael Quigley - San Carlos CA, US
Virginie Lafont - Lawrence Twp NJ, US
Ginger C. Rakestraw - Somerville MA, US
Linda Liang - Mountain View CA, US
International Classification:
C07K 16/40
A61K 47/68
A61P 35/00
C07K 16/28
Abstract:
This disclosure provides isolated antibodies that bind specifically to MerTK expressed on the surface of a cell and inhibit efferocytosis by the MerTK-expressing cell. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-MerTK antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1 or anti-PD-L1 antibody.

Fibronectin Based Scaffold Domain Proteins That Bind Pcsk9

View page
US Patent:
20210277089, Sep 9, 2021
Filed:
Feb 16, 2021
Appl. No.:
17/177179
Inventors:
- Princeton NJ, US
Jonathan H. DAVIS - Auburndale MA, US
Sharon T. CLOAD - Cambridge MA, US
Fabienne M. DENHEZ - Arlington MA, US
Dasa LIPOVSEK - Cambridge MA, US
Ching-Hsiung Frederick LO - Pennington NJ, US
Chee Meng LOW - Allston MA, US
Bowman MIAO - Churchville PA, US
Tracy S. MITCHELL - Andover MA, US
Rex A. PARKER - Titusville NJ, US
Ginger C. RAKESTRAW - Cambridge MA, US
Katie A. RUSSO - Watertown MA, US
Doree F. SITKOFF - Dresher PA, US
International Classification:
C07K 14/78
A61K 38/39
C12N 9/64
A61K 47/60
A61K 47/54
C07K 16/18
C07K 16/40
Abstract:
The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

Antagonistic Cd40 Monoclonal Antibodies And Uses Thereof

View page
US Patent:
20210054090, Feb 25, 2021
Filed:
Oct 26, 2020
Appl. No.:
17/080626
Inventors:
- Princeton NJ, US
Mary STRUTHERS - Edison NJ, US
Akbar NAYEEM - Newtown PA, US
Ginger RAKESTRAW - Somerville MA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07K 16/28
A61K 47/68
A61K 39/395
A61K 45/06
Abstract:
The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
Control profile
Ginger C Rakestraw from Somerville, MA, age ~44 Get Report